Redeye initiates coverage of Clinical Laserthermia Systems

We are initiating coverage of Clinical Laserthermia Systems. With approvals already secured both in Europe and the US for its laser treatment of tumors, CLS offers significant long-term potential - particularly as recurring disposables will be its main source of sales. We view a 5% or higher market share in its cancer indications as achievable within 10 years, by when revenues should be up to SEK 1bn.

Read more and download the research update: http://bit.ly/2S7AT16

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/